Patents by Inventor K. Mark Bushell

K. Mark Bushell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT AND ANTI-CD96 ANTIBODIES
    Publication number: 20240141039
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Application
    Filed: June 13, 2023
    Publication date: May 2, 2024
    Inventors: Dhan Sidhartha CHAND, Zahra JAWAD, Olga IGNATOVICH, Nicola Anne RAMSAY, Spencer CAMPBELL, Beth WENSLEY, Emmanuel Cyrille Pascal BRIEND, K. Mark BUSHELL, Benjamin Maxime MORIN, Veronica Franciszka ILKOW
  • Anti-TIGIT and anti-CD96 antibodies
    Patent number: 11718669
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: August 8, 2023
    Assignee: AGENUS INC.
    Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
  • Antibodies that specifically bind human CD96
    Patent number: 11680098
    Abstract: The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: June 20, 2023
    Assignee: AGENUS INC.
    Inventors: Dhan Sidhartha Chand, Randi Barbara Gombos, Olga Ignatovich, Nicola Anne Ramsay, K. Mark Bushell, Emmanuel Cyrille Pascal Briend
  • ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20230014036
    Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.
    Type: Application
    Filed: August 10, 2022
    Publication date: January 19, 2023
    Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220389095
    Abstract: The instant disclosure provides isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: May 4, 2022
    Publication date: December 8, 2022
    Inventors: Olga IGNATOVICH, K. Mark BUSHELL, Dhan Sidhartha CHAND, Beth WENSLEY
  • ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210101977
    Abstract: The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: August 31, 2020
    Publication date: April 8, 2021
    Inventors: Dhan Sidhartha Chand, Randi Barbara Gombos, Olga Ignatovich, Nicola Anne Ramsay, K. Mark Bushell, Emmanuel Cyrille Pascal Briend